Russell Investments Group
NMRA icon

Russell Investments Group’s Neumora Therapeutics NMRA Stock Holding History

Russell Investments Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-73,812
Closed -$55.9K – 4198
2025
Q2 		$55.9K Buy
73,812
+71,350
+2,898% +$54.1K ﹤0.01% 2955
2025
Q1 		$2.46K Buy
+2,462
New +$4.22K ﹤0.01% 3483

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Russell Investments Group's NMRA Position: Q3 2025 in Review

Russell Investments Group sold out of Neumora Therapeutics (NMRA) in Q3 2025, closing a stake of 73,812 shares — an estimated $55.9K sold.

Russell Investments Group first reported a position in NMRA in Q1 2025 and held it in 2 quarters. The position peaked at $55.9K in Q2 2025. 93 funds tracked by Wall St. Rank hold NMRA as of Q3 2025.

  • Russell Investments Group reported no remaining Neumora Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Russell Investments Group sold 73,812 Neumora Therapeutics shares in Q3 2025, an estimated $55.9K.
  • Russell Investments Group first reported a position in Neumora Therapeutics in Q1 2025 and held it in 2 quarters.
  • Russell Investments Group's Neumora Therapeutics position peaked at $55.9K in Q2 2025.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2025.

Based on Russell Investments Group's 13F filing for Q3 2025, filed 13 Nov 2025.